University of Toronto-Toronto Western Hospital
Welcome,         Profile    Billing    Logout  
 6 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wong, David
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Active, not recruiting
3
80
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
05/24
02/25
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease

Not yet recruiting
2
393
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline
Liver Diseases, Alcoholic
12/26
03/27
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

Recruiting
N/A
5000
Canada, US
All approved therapies for the treatment of Chronic Hepatitis B (CHB)
Target PharmaSolutions, Inc.
Hepatitis B, Hepatitis, Liver Diseases
01/26
01/26
Feld, Jordan
NCT04017338: Transplantation Using Hepatitis C Positive Donors, A Safety Trial

Recruiting
3
40
Canada
Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet, Maviret, Ezetimibe 10Mg Oral Tablet, Ex Vivo Lung Perfusion, Normothermic EVLP
Jordan Feld, University Health Network, Toronto
Lung Transplant Infection, Heart Transplant Infection, Kidney Transplant Infection, Kidney Pancreas Infection, Hepatitis C
12/20
12/24
NCT04967430: TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19

Active, not recruiting
3
763
Canada
Peginterferon Lambda-1A, Placebo
University Health Network, Toronto
Sars-CoV2, Covid19
03/22
06/22
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed
3
407
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals
Hepatitis Delta Virus
10/22
03/23
ILIAD, NCT04354259: Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19

Completed
2
157
Canada, RoW
Peginterferon Lambda-1A, placebo
University Health Network, Toronto, Michael Garron Hospital
Sars-CoV2, Covid-19
08/22
12/22
B-Fine, NCT04544956: A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B

Completed
2
12
Europe, Canada, US
GSK3228836, Nucleos(t)ide therapy
GlaxoSmithKline
Hepatitis B
11/23
11/23
NCT06216470: Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION]

Recruiting
2
15
Canada
VIR-3434
University Health Network, Toronto
Hepatitis B, Chronic
12/29
12/29
B-Sure, NCT04954859 / 2021-000554-26: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants

Recruiting
2
450
Europe, Canada, Japan, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Hepatitis B
02/29
02/29
RAPID-HCV, NCT04677153: Rapid HCV Treatment Access for Persons Who Use Drugs

Active, not recruiting
N/A
124
Canada, US
Test and treat plus peer mentors, On-site treatment with peer support HCV treatment implementation strategy, Usual care, Standard of care referral HCV treatment implementation strategy
Johns Hopkins University, AbbVie
Hepatitis C Virus Infection, Response to Therapy of
02/24
02/25

Download Options